News|Articles|May 28, 2026
Policy Fatigue: The Future of Patient Access in Pharma
Author(s)Dane Schroeder, BGB Group
Key Takeaways
- ”, written as complete sentences, without repetitive openers.
Across the pharmaceutical industry, coverage does not inherently mean access. As a result, the industry must overcome "policy fatigue" by rethinking access strategies, pricing models, and organizational integration to bridge the critical gap between product coverage and real-world patient access.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
2
FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy
3
Why Breakthrough Cell and Gene Therapies Still Fail at the Finish Line
4
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
5